Skip to main content
Norris Medicines Ltd. logo

Norris Medicines Ltd. — Investor Relations & Filings

Ticker · 524414 ISIN · INE744C01029 BSE.NS Manufacturing
Open in API
Filings indexed 4 across all filing types
Latest filing 2026-05-30 Earnings Release
Country IN India
Listing BSE.NS 524414

About Norris Medicines Ltd.

https://www.norrispharma.com

Norris Medicines Ltd. is a pharmaceutical organization focused on the development, manufacture, and commercialization of a broad spectrum of pharmaceutical formulations. The company's product portfolio includes diverse dosage forms such as tablets, capsules, liquid orals, ointments, and small volume parenterals. These offerings span various therapeutic categories, including anti-infectives, analgesics, anti-inflammatory drugs, and gastrointestinal medications. The company operates manufacturing facilities that adhere to Good Manufacturing Practices (GMP) to ensure product quality and safety. Norris Medicines Ltd. caters to a wide range of healthcare needs across multiple markets, leveraging its technical expertise and integrated production processes to deliver essential medicinal products.

Recent filings

Filing Released Lang Actions
Appointment of Internal Auditor w.e.f 30.05.2026
Earnings Release Classification · 78% confidence The document is an official outcome of a board meeting filed under SEBI LODR Regulations 30 & 33, disclosing and annexing the audited financial results (quarter and full year ended March 31, 2026) along with the independent auditor’s report. It is not a full annual report (10-K) or standalone audit report (AR), nor is it merely a publication announcement (RPA/RNS) or management discussion. It fits the definition of an initial announcement of periodical financial results (earnings release). FY 2026
2026-05-30 English
As per attachment.
Interim / Quarterly Report Classification · 85% confidence The document is a Board meeting outcome filed under SEBI Regulations 30 & 33, including the Audited Financial Results for the quarter and year ended March 31, 2026, along with the Independent Auditor’s Report and key financial statements (profit & loss, assets & liabilities, cash flows). It contains substantive financial data beyond mere highlights or link references. This matches the definition of an Interim/Quarterly Report (IR) rather than an earnings release, annual report, or simple publication announcement. FY 2026
2026-05-30 English
As per attachment.
Regulatory Filings Classification · 85% confidence The document is a formal disclosure to the stock exchange under SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015, providing audited quarterly and year-end financial results and the independent auditor’s report. It is not the full annual report (10-K) nor simply an earnings release (ER), but a regulatory announcement of financial results filed with the exchange. It does not constitute the complete report itself but is a regulatory disclosure, making “Regulatory Filings (RNS)” the appropriate category.
2026-05-30 English
Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve As per attachment.
Regulatory Filings Classification · 82% confidence The document is an intimation under Regulation 29 of SEBI LODR notifying the stock exchange of a forthcoming Board meeting to approve audited financial results for the quarter and year ended March 31, 2026. It does not contain the actual financial results or reports, nor is it a proxy, dividend notice, or related to change in management. It is a regulatory announcement of a board meeting under listing obligations—best classified under Regulatory Filings (RNS) as a general regulatory announcement.
2026-05-25 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.